213 related articles for article (PubMed ID: 18582946)
1. Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)].
Scolaro C; Hartinger CG; Allardyce CS; Keppler BK; Dyson PJ
J Inorg Biochem; 2008 Sep; 102(9):1743-8. PubMed ID: 18582946
[TBL] [Abstract][Full Text] [Related]
2. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
Scolaro C; Chaplin AB; Hartinger CG; Bergamo A; Cocchietto M; Keppler BK; Sava G; Dyson PJ
Dalton Trans; 2007 Nov; (43):5065-72. PubMed ID: 17992291
[TBL] [Abstract][Full Text] [Related]
3. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
4. Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity.
Hartinger CG; Casini A; Duhot C; Tsybin YO; Messori L; Dyson PJ
J Inorg Biochem; 2008 Dec; 102(12):2136-41. PubMed ID: 18834634
[TBL] [Abstract][Full Text] [Related]
5. Novel half-sandwich Ru(II)-hydroxamate complexes: synthesis, characterization and equilibrium study in aqueous solution.
Buglyó P; Farkas E
Dalton Trans; 2009 Oct; (38):8063-70. PubMed ID: 19771370
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
7. In vitro ruthenation of human breast cancer suppressor gene 1 (BRCA1) by the antimetastasis compound RAPTA-C and its analogue CarboRAPTA-C.
Ratanaphan A; Temboot P; Dyson PJ
Chem Biodivers; 2010 May; 7(5):1290-302. PubMed ID: 20491084
[TBL] [Abstract][Full Text] [Related]
8. Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action.
Casini A; Karotki A; Gabbiani C; Rugi F; Vašák M; Messori L; Dyson PJ
Metallomics; 2009 Sep; 1(5):434-41. PubMed ID: 21305148
[TBL] [Abstract][Full Text] [Related]
9. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
10. Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.
Kilpin KJ; Cammack SM; Clavel CM; Dyson PJ
Dalton Trans; 2013 Feb; 42(6):2008-14. PubMed ID: 23187957
[TBL] [Abstract][Full Text] [Related]
11. Metabolization of [Ru(eta(6)-C (6)H (5)CF (3))(pta)Cl (2)]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand.
Egger AE; Hartinger CG; Renfrew AK; Dyson PJ
J Biol Inorg Chem; 2010 Aug; 15(6):919-27. PubMed ID: 20364440
[TBL] [Abstract][Full Text] [Related]
12. Hydrolytic behaviour and chloride ion binding capability of [Ru(η6-p-cym)(H2O)3]2+: a solution equilibrium study.
Bíró L; Farkas E; Buglyó P
Dalton Trans; 2012 Jan; 41(1):285-91. PubMed ID: 22051630
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts.
Wang F; Chen H; Parsons S; Oswald ID; Davidson JE; Sadler PJ
Chemistry; 2003 Dec; 9(23):5810-20. PubMed ID: 14673852
[TBL] [Abstract][Full Text] [Related]
14. Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds.
Dorcier A; Hartinger CG; Scopelliti R; Fish RH; Keppler BK; Dyson PJ
J Inorg Biochem; 2008; 102(5-6):1066-76. PubMed ID: 18086499
[TBL] [Abstract][Full Text] [Related]
15. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
16. 106Ru radiolabelling of the antitumour complex [(eta6-fluorene)Ru(en)Cl]PF6.
Hoeschele JD; Habtemariam A; Muir J; Sadler PJ
Dalton Trans; 2007 Nov; (43):4974-9. PubMed ID: 17992282
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
[TBL] [Abstract][Full Text] [Related]
18. Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes.
Fernández R; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Chemistry; 2004 Oct; 10(20):5173-9. PubMed ID: 15372674
[TBL] [Abstract][Full Text] [Related]
19. Versatile coordination of acetazolamide to ruthenium(ii) p-cymene complexes and preliminary cytotoxicity studies.
Biancalana L; Batchelor LK; Ciancaleoni G; Zacchini S; Pampaloni G; Dyson PJ; Marchetti F
Dalton Trans; 2018 Jul; 47(28):9367-9384. PubMed ID: 29951658
[TBL] [Abstract][Full Text] [Related]
20. Solution equilibria of anticancer ruthenium(II)-(η(6)-p-cymene)-hydroxy(thio)pyr(id)one complexes: impact of sulfur vs. oxygen donor systems on the speciation and bioactivity.
Enyedy EA; Sija E; Jakusch T; Hartinger CG; Kandioller W; Keppler BK; Kiss T
J Inorg Biochem; 2013 Oct; 127():161-8. PubMed ID: 23721887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]